Company Profile
Stratatech Corporation is a privately-held regenerative medicine company focused on the development of cell-based, tissue-engineered skin substitute products for therapeutic and research uses. Our first biologically-active wound care product was recently evaluated in a Phase I/II clinical trial and a pipeline of wound care products engineered to improve healing and reduce infection in the wound bed is in development. We recently introduced a human skin model an alternative to animal testing for consumer product testing, drug discovery and toxicity screening.
Stratatech was founded by Lynn Allen-Hoffmann, Ph.D. in 2000 to commercialize a unique discovery that enables the production of therapeutic, biologically-active wound care and testing products. These products use the NIKS® human keratinocyte cell line, which was discovered at the University of Wisconsin-Madison School of Medicine and Public Health. NIKS® cells form tissue with the structure and function of human skin when properly cultured. Stratatech has exclusive, worldwide commercialization rights in all fields of use to the original NIKS® cell line patent issued to the Wisconsin Alumni Research Foundation (WARF) and to six subsequent NIKS® cell line related patents filed by WARF. In addition, Stratatech has 11 issued and numerous pending patents related to its core technology.
StrataGraft® skin tissue, Stratatech’s first product, was recently evaluated in a Phase I/II clinical trial as a temporary skin replacement prior to autografting. The ExpressGraft™ pipeline of products is the next generation of enhanced wound care therapies being developed by the company using genetically modified NIKS® cells. In addition to these biologically-active wound care therapeutics, the company also produces the StrataTest® human skin model, an alternative to animal testing for use by pharmaceutical, biotechnology and consumer product companies.
Stratatech offices and laboratories are located in the University Research Park in Madison, Wisconsin. Stratatech currently employs approximately twenty-five individuals, including seven Ph.D. scientists.